Search company, investor...


Founded Year



Growth Equity | Alive

About Xenome

Xenome focuses on the discovery and development of peptide pharmaceuticals based on libraries of venom and related peptides.

Headquarters Location

120 Meiers Road Indooroopilly Building 3



Missing: Xenome's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Xenome's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Xenome Patents

Xenome has filed 1 patent.

patents chart

Application Date

Grant Date


Related Topics




Analgesics, Piperidines, Synthetic opioids, Amines, Phenols


Application Date


Grant Date



Related Topics

Analgesics, Piperidines, Synthetic opioids, Amines, Phenols



Latest Xenome News

Xenome Ltd. Mergers Acquisitions MA Partnerships Alliances and Investment Report Prices from USD $350

Nov 30, 2016

Home » Topics » Alliances, mergers acquisitions and partnerships » Latest News » Xenome, Ltd. Mergers Acquisitions MA, Partnerships Alliances and Investment Report Prices from USD $350 Summary MarketLine's Company Mergers Acquisitions MA, Partnerships Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. MarketLines' Xenome, Ltd. Mergers Acquisitions MA, Partnerships Alliances and Investments report includes business description, detailed reports on mergers and acquisitions MA, divestments, capital raisings, venture capital investments, ownership and partnership transactions undertaken by Xenome, Ltd. since January 2007. Key Findings Provides intelligence on Xenome, Ltd. MA, strategic partnerships and alliances, capital raising and private equity transactions. Detailed reports of various financial transactions undertaken by Xenome, Ltd. and its subsidiaries since 2007. Information about key financial and legal advisors for Xenome, Ltd.'s financial deals transactions. Financial deals tables and charts covering deal value and volumes trend, deal types and geographybased deal activity. ReasonsToBuy Access comprehensive financial deals data along with charts and graph covering MA, private equity, and partnerships and alliances. Form an independent opinion about Xenome, Ltd.'s growth strategies through the organic and inorganic activities undertaken since 2007. Track your competitors' business structure and growth strategies. Related Biotechnology, Pharmaceutical and Healthcare News

Xenome Frequently Asked Questions (FAQ)

  • When was Xenome founded?

    Xenome was founded in 2000.

  • What is Xenome's latest funding round?

    Xenome's latest funding round is Growth Equity.

  • Who are the investors of Xenome?

    Investors of Xenome include GBS Venture Partners, Queensland BioCapital Funds, Amylin Pharmaceuticals and TargeGen.

  • Who are Xenome's competitors?

    Competitors of Xenome include ISA Pharmaceuticals, Adastra Pharmaceuticals, Rigel Pharmaceuticals, Actinobac Biomed, Azevan Pharmaceuticals and 13 more.

Compare Xenome to Competitors

Alinea Pharmaceuticals

Alinea Pharmaceuticals, Inc. offers pharmaceuticals for diabetes and related metabolic disorders

Diasome Pharmaceuticals

Diasome Pharmaceuticals develops hepatocyte directed vesicle technology, an insulin additive, to lessen the instances of high and low blood sugar levels in people with diabetes to improve disease management and quality of life. The company was founded in 2004 and is based in Cleveland, Ohio.

Hormos Medical

Hormos Medical, A Subsidiary Of Quatrx Pharmaceuticals, Focuses On Developing Therapies For Endocrine, Metabolic And Cardiovascular Diseases.

Meditrina Pharmaceuticals

Meditrina Pharmaceuticals, Inc. is a clinical-stage, specialty pharmaceutical company focused on developing and commercializing therapies that treat women's reproductive system disorders, with an initial focus on gynecologic and aromatase-mediated conditions with serious unmet medical needs.

Q Therapeutics

Q Therapeutics, Inc. is developing glial cell-based therapeutic products for central nervous system disorders in which a disease or injury inhibits normal myelin growth and enzyme performance.

Adastra Pharmaceuticals

Adastra Pharmaceuticals is a private, clinical-stage biopharmaceutical company committed to providing responsible solutions to advance patient care in oncology. Its vision is to identify, develop, and deliver to patients important new therapies for diseases with significant unmet needs. This commitment is epitomized by its lead clinical candidate, zotiraciclib, which is initially being developed for the treatment of high-grade gliomas (HGG) and diffuse intrinsic pontine glioma (DIPG), two forms of brain cancer characterized by Myc overexpression. Adastra possesses a rich history of institutional and academic collaboration, including ongoing clinical research programs with the National Cancer Institute (NCI) and the European Organisation for Research and Treatment of Cancer (EORTC).

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.